Small Molecules for Precision Medicine

Proteus Syndrome Phase 1 Data Presentation

ArQule to Present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019

ArQule Announces Preliminary Results from Its Phase 1/2 Study of Miransertib (ARQ 092), in Patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an Oral Presentation at the European Society of Human Genetics Conference